Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 597

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 597
---
 to account for under the fair value
option. Until settlement, these notes payable are remeasured at fair value at each reporting period with the changes in fair value recorded in the statement of operations.

Other (Expense) Income, Net

Other
(expense) income, net consists of items that are of a non-recurring nature and primarily relate to items that are immaterial.

Net (Loss) Income Attributable to Noncontrolling Interest

Net (loss) income attributable to noncontrolling interest reflects investors’ share of net (loss) income in Kineta’s majority owned
subsidiary.

Segment Reporting

Kineta operates as a single reportable segment, which is primarily engaged in the development of next-generation immunotherapies. Kineta has
concluded that its President is the chief operating decision maker (“CODM”) for the year ended December 31, 2024 and its former CEO and President together were the CODM for the year ended December 31, 2023. The CODM reviews the
Company’s performance and allocates resources on a consolidated basis.

Kineta did not generate revenue for the year ended December
31, 2024 and generated license and collaboration revenue from one customer located in the United States for the year ended December 31, 2023.

396

Results of Operations Comparison of the Years Ended December 31, 2024 and 2023 The following table summarizes Kineta’s results of operations for the periods presented:

| Revenues:                                                 |     | Years Ended December 31, 
 2024                     
 (in thousands)           |         |   |     | 2023 |         |   |     | Change |        |   |
|:----------------------------------------------------------|:----|:-------------------------|--------:|:--|:----|:-----|--------:|:--|:----|:-------|-------:|:--|
| Licensing revenues                                        |     | $                        |       — |   |     | $    |   5,000 |   |     | $      | (5,000 | ) |
| Collaboration revenues                                    |     |                          |       — |   |     |      |     442 |   |     |        |   (442 | ) |
| Total revenues                                            |     |                          |       — |   |     |      |   5,442 |   |     |        | (5,442 | ) |
| Operating expenses:                                       |     |                          |